Literature DB >> 3282534

Cyclosporin-verapamil interaction.

R A Robson1, M Fraenkel, L J Barratt, D J Birkett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3282534      PMCID： PMC1386367          DOI： 10.1111/j.1365-2125.1988.tb03321.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

1.  Cyclosporin-diltiazem interaction.

Authors:  J M Pochet; Y Pirson
Journal:  Lancet       Date:  1986-04-26       Impact factor: 79.321

2.  Influence of diltiazem on cyclosporin clearance.

Authors:  J M Griño; I Sabate; A M Castelao; J Alsina
Journal:  Lancet       Date:  1986-06-14       Impact factor: 79.321

3.  Increased serum theophylline concentrations secondary to oral verapamil.

Authors:  T G Burnakis; M Seldon; A D Czaplicki
Journal:  Clin Pharm       Date:  1983 Sep-Oct

4.  Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy.

Authors:  L A Bauer; M Stenwall; J R Horn; R Davis; K Opheim; L Greene
Journal:  Clin Pharmacol Ther       Date:  1986-08       Impact factor: 6.875

5.  Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction.

Authors:  G J Macphee; G T McInnes; G G Thompson; M J Brodie
Journal:  Lancet       Date:  1986-03-29       Impact factor: 79.321
  5 in total
  8 in total

Review 1.  Pharmacokinetic drug interactions with cyclosporin (Part II).

Authors:  G C Yee; T R McGuire
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 3.  Primary care of the renal transplant patient.

Authors:  J D Pirsch; R Friedman
Journal:  J Gen Intern Med       Date:  1994-01       Impact factor: 5.128

Review 4.  The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations.

Authors:  T E Jones
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

5.  A sandwiched microarray platform for benchtop cell-based high throughput screening.

Authors:  Jinhui Wu; Ian Wheeldon; Yuqi Guo; Tingli Lu; Yanan Du; Ben Wang; Jiankang He; Yiqiao Hu; Ali Khademhosseini
Journal:  Biomaterials       Date:  2010-10-20       Impact factor: 12.479

6.  Nifedipine, verapamil and cyclosporin A pharmacokinetics in children.

Authors:  M R Ogborn; J F Crocker; P C Grimm
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

7.  Pharmacokinetic interaction between cyclosporin and diltiazem.

Authors:  J Brockmöller; H H Neumayer; K Wagner; W Weber; G Heinemeyer; H Kewitz; I Roots
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

8.  The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients.

Authors:  J F Crocker; K W Renton; T L LeVatte; D H McLellan
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.